-

Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock.

The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health’s blood test to screen for colorectal cancer in average-risk adults.

The panel meeting is scheduled to begin at 9:30 a.m. ET.

FDA advisory committees provide independent expert advice and non-binding recommendations to the FDA on certain products to help the agency make sound decisions based on the available science.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Contacts

Investors:
Zarak Khurshid
investors@guardanthealth.com

Media:
Mike Weist
press@guardanthealth.com
+1 650-647-3643

Industry:

Guardant Health, Inc.

NASDAQ:GH
Release Versions
English

Contacts

Investors:
Zarak Khurshid
investors@guardanthealth.com

Media:
Mike Weist
press@guardanthealth.com
+1 650-647-3643

More News From Guardant Health, Inc.

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who a...

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first...

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) through one of the largest diagnostic ecosystems in the United States. Shield is the first and only blood test to rec...
Back to Newsroom